CN Patent

CN119700772A — Tyk2抑制剂的延长释放剂型

Assigned to Bristol Myers Squibb Co · Expires 2025-03-28 · 1y expired

What this patent protects

提供了包含固体聚合物基质中的固体无定形6‑(环丙烷酰胺基)‑4‑((2‑甲氧基‑3‑(1‑甲基‑1H‑1,2,4‑三唑‑3‑基)苯基)氨基)‑N‑(甲基‑d3)哒嗪‑3‑甲酰胺(式(I)；BMS‑986165)的分散体(例如，喷雾干燥分散体)的稳定和可生物利用的延长释放配制品和剂型以用于治疗自身免疫性和自身炎性疾病如炎性肠病(IBD)和银屑病。

USPTO Abstract

提供了包含固体聚合物基质中的固体无定形6‑(环丙烷酰胺基)‑4‑((2‑甲氧基‑3‑(1‑甲基‑1H‑1,2,4‑三唑‑3‑基)苯基)氨基)‑N‑(甲基‑d3)哒嗪‑3‑甲酰胺(式(I)；BMS‑986165)的分散体(例如，喷雾干燥分散体)的稳定和可生物利用的延长释放配制品和剂型以用于治疗自身免疫性和自身炎性疾病如炎性肠病(IBD)和银屑病。

Drugs covered by this patent

Patent Metadata

Patent number
CN119700772A
Jurisdiction
CN
Classification
—
Expires
2025-03-28
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.